Kezar Life Sciences (NASDAQ:KZR) traded lower on Tuesday after the company announced its Q4 2024 financial results alongside data from a mid-stage trial for its lead asset zetomipzomib in patients ...

KEZAR LIFE SCIENCES ($KZR) posted quarterly earnings results on Tuesday, March 25th. The company reported earnings of -$2.77 per share, beating estimates of -$2.91 by ...

Also Read: Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study In the ITT population: Without regard to ...

Kezar Life Sciences (KZR) reported topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a selective immunoproteasome inhibitor, in patients with autoimmune hepatitis ...

Neighbours at Millbrook Towers were left speechless after emergency services were called to the tower block on the morning of Saturday, January 6, 2024, following the sudden death of a baby.

After decades of nomadic land-based living, a couple decided to search for a fishing vessel that could take them on their next journey. How far would $350,000 go? By Michele Lerner Students and ...

After hours: March 25 at 5:40:50 PM EDT Vertex Baseline Delta ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.